FePt@CoS2 yolk-shell nanocrystals as a potent agent to kill HeLa cells
FePt@CoS2 yolk-shell nanocrystals as a potent agent to kill HeLa cells
复制标题
DOI：
10.1021/ja067785e
复制
发表时间：
2007-02-07
影响因子：
15
通讯作者：
Xu, Bing
中科院分区：
文献类型：
--
作者：
Gao, Jinhao;Liang, Gaolin;Xu, Bing
我们报道了对一种新型工程纳米材料——FePt@CoS₂核壳纳米晶体的细胞毒性评估。该材料是以FePt纳米粒子为晶种，通过柯肯达尔效应机制合成的。通过MTT法评估，FePt@CoS₂核壳纳米晶体的细胞毒性显示出其半数抑制浓度（IC₅₀）（对HeLa细胞为35.5 ± 4.7纳克铂/毫升）远低于顺铂（230纳克铂/毫升）。在对照实验中，半胱氨酸修饰的FePt纳米粒子的IC₅₀为12.0 ± 0.9微克铂/毫升。透射电子显微镜证实了细胞对FePt@CoS₂纳米晶体的摄取，磁性分析（超导量子干涉仪）证明了细胞摄取后FePt纳米粒子从核壳纳米结构中释放出来。这些结果意义重大，因为在过去30年中用于临床试验的铂基复合物几乎没有一种显示出比母体药物顺铂更高的活性。FePt@CoS₂核壳纳米晶体极高的毒性（就铂而言，约为顺铂的7倍）可能会导致一种抗癌纳米药物的新设计。
We report the evaluation of cytotoxicity of a new type of engineered nanomaterials, FePt@CoS2 yolk-shell nanocrystals, synthesized by the mechanism of the Kirkendall effect when FePt nanoparticles serve as the seeds. The cytotoxicity of FePt@CoS2 yolk-shell nanocrystals, evaluated by MTT assay, shows a much lower IC50 (35.5 +/- 4.7 ng of Pt/mL for HeLa cell) than that of cisplatin (230 ng of Pt/mL). In the control experiment, cysteine-modified FePt nanoparticles exhibit IC50 at 12.0 +/- 0.9 mu g of Pt/mL. Transmission electron microscopy confirms the cellular uptake of FePt@CoS2 nanocrystals, and the magnetic properties analysis (SQUID) proves the release of FePt nanoparticles from the yolk-shell nanostructures after cellular uptake. These results are significant because almost none of the platinum-based complexes produced for clinical trials in the past 3 decades have shown higher activity than that of the parent drug, cisplatin. The exceptionally high toxicity of FePt@CoS2 yolk-shell nanocrystals (about 7 times higher than that of cisplatin in terms of Pt) may lead to a new design of an anticancer nanomedicine.